Motilal Oswal, Anthem Biosciences Ltd
India’s fastest-growing CRDMO player: Anthem Biosciences Ltd (ABL) is an innovation & technology focused Contract Research, Development, and Manufacturing Organization (CRDMO - 82% of FY25 revenue). It has fully integrated operations (drug discovery, development, and manufacturing), with integrated New Chemical Entity (NCE) and New Biological Entity (NBE) capabilities. It’s the fastest Indian CRDMO to reach ₹1,000 crore revenue within 14 years of operations.
Valuation and Outlook
We recommend investors to ‘Subscribe’ to the issue. At ₹570, issue is priced at 71x FY25 P/E as compared to the listed peers average of ~95x. ABL, the only CRDMO in India with robust capabilities in both small molecules and biologics.
For all IPO report, click here
Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on moneycontrol.com are their own, and not that of the website or its management. Moneycontrol.com advises users to check with certified experts before taking any investment decisions.
Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!
Find the best of Al News in one place, specially curated for you every weekend.
Stay on top of the latest tech trends and biggest startup news.
